Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Denosumab Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Denosumab Products for Osteoporosis and Cancer-Treatment-Related Bone Loss

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA Medicare Advantage coverage and prior authorization for Prolia and specified denosumab biosimilar products. It defines covered indications, preferred-product exception criteria, authorization durations, continuation requirements, and dosing controls.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyDenosumab Products for Osteoporosis and Cancer-Treatment-Related Bone Loss
    Policy CodePolicy N/A
    Change TypeOff-cycle revision with preferred-product update
    Effective DateOctober 1, 2026
    Last ReviewJun 1, 2025
    Next Review DateN/A
    Key ActionPrior authorization is required; providers should use the HMSA medical specialty drug policy website fax form.
    SourceLink
    POLICY UPDATE CHANGES

    A preferred-product grid and non-preferred product exception criteria were added.

    The policy received an off-cycle revision effective October 1, 2026.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    9Denosumab products named
    5FDA-approved indication categories
    3Compendial use categories
    365 daysPrior-use lookback
    24 monthsAuthorization duration for selected indications
    PA requiredAdministrative requirement

    Covered Indications

    Osteoporosis treatment

    Indefinite authorization may be granted.

    Osteoporosis treatment: The member has osteoporosis and is a man or postmenopausal woman at high risk for fracture.

    High risk for fracture includes a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance of other available osteoporosis therapy.

    Osteoporosis prevention

    Indefinite authorization may be granted.

    Osteoporosis prevention: The member is an osteopenic postmenopausal woman requiring prevention of osteoporosis.

    Increasing bone mass in prostate cancer

    Authorization of 24 months may be granted.

    Increasing bone mass in prostate cancer: The member is a man at high risk for fracture who is receiving androgen deprivation therapy for prostate cancer.

    Increasing bone mass in breast cancer

    Authorization of 24 months may be granted.

    Increasing bone mass in breast cancer: The member is a woman at high risk for fracture who is receiving adjuvant aromatase inhibition therapy for breast cancer.

    Glucocorticoid-induced osteoporosis

    Authorization of 24 months may be granted.

    Glucocorticoid-induced osteoporosis: The member is a man or woman with glucocorticoid-induced osteoporosis at high risk for fracture.

    Qualifying systemic glucocorticoid exposure is a daily dosage equivalent to at least 7.5 mg of prednisone, with expected continuation for at least 6 months.

    Continuation therapy: osteoporosis

    Indefinite authorization may be granted when all criteria are met.

    Continuation of osteoporosis therapy

    • The member is currently receiving therapy with the requested drug.
    • The requested drug is being used for osteoporosis treatment or osteoporosis prevention.
    • The member is receiving benefit from therapy.

      Benefit means disease stability or disease improvement.

    Continuation therapy: all other indications

    Authorization for 12 months may be granted when all criteria are met.

    Continuation of therapy for other indications

    • The member is currently receiving therapy with the requested drug.
    • The requested drug is being used to treat a covered indication other than osteoporosis treatment or prevention.
    • The member is receiving benefit from therapy.

      Benefit means disease stability or disease improvement.

    Clinical Thresholds and Product History

    Systemic prednisone-equivalent dose
    Dose thresholdAt least 7.5 mg daily prednisone-equivalent
    Medication typeSystemic glucocorticoid
    Applicable conditionGlucocorticoid-induced osteoporosis
    Expected glucocorticoid duration
    Expected durationAt least 6 months
    Treatment statusThe member may be initiating or continuing systemic glucocorticoids
    Applicable conditionGlucocorticoid-induced osteoporosis

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit requests using the fax form available on the HMSA medical specialty drug policy website.

    • Refer to the HMSA medical specialty drug policy website for the required fax form.
    Step Therapy

    Use Preferred Bildyos First

    Preferred-product requirements apply to members who are new to treatment with a non-preferred product. Bildyos (denosumab-nxxp) is preferred; coverage of a non-preferred product requires an applicable clinical exception.

    • Preferred product: Bildyos (denosumab-nxxp).
    • Non-preferred products include Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Prolia, and Stoboclo.
    • The step-therapy preferred-drug criteria do not apply to new or existing FDA-approved products that are not listed, or to requests for an indication that is not FDA-approved for the preferred product.

    Policy Background

    Denosumab products are covered for osteoporosis treatment in men and postmenopausal women at high risk for fracture, and for osteoporosis prevention in osteopenic postmenopausal women. The policy also recognizes selected compendial uses, including prevention of osteoporosis in osteopenic postmenopausal women.

    Coverage also includes treatment-related bone loss associated with androgen deprivation therapy for prostate cancer and adjuvant aromatase inhibition therapy for breast cancer. Additional covered use includes glucocorticoid-induced osteoporosis in men and women at high risk for fracture; cancer- and glucocorticoid-related indications may receive authorization for 24 months, while osteoporosis treatment and prevention may receive indefinite authorization when criteria are met.

    Clinical Definitions

    High risk for fracture
    Osteoporotic fracture historyA history of osteoporotic fracture
    Multiple risk factorsMultiple risk factors for fracture
    Other osteoporosis therapyFailure or intolerance of other available osteoporosis therapy, where specified
    Qualifying glucocorticoid exposure
    Daily dosageEquivalent to at least 7.5 mg of prednisone daily
    Glucocorticoid statusThe member is initiating or continuing systemic glucocorticoids
    Expected continuation

    Initial Therapy

    Initial therapy: osteoporosis treatment

    Indefinite authorization may be granted for osteoporosis treatment.

    Osteoporosis treatment: The member has osteoporosis and is a man or postmenopausal woman at high risk for fracture.Indefinite authorization

    High risk for fracture includes a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance of other available osteoporosis therapy.

    Initial therapy: osteoporosis prevention

    Indefinite authorization may be granted for osteoporosis prevention.

    Osteoporosis prevention: The member is an osteopenic postmenopausal woman.Indefinite authorization

    Continuation Therapy

    Continuation: osteoporosis

    For osteoporosis treatment or prevention, indefinite authorization may be granted when all criteria are met.

    Osteoporosis continuation

    • The member is currently receiving the requested drug.
    • The requested drug is being used for osteoporosis treatment or prevention.
    • The member is receiving benefit from therapy.

      Benefit means disease stability or disease improvement.

    Continuation: all other indications

    For all other covered indications, authorization for 12 months may be granted when all criteria are met.

    Other-indication continuation

    Preferred Product Requirement

    StepProductCoverage requirement
    1Bildyos (denosumab-nxxp)Preferred product; use before a non-preferred denosumab product.
    2Non-preferred denosumab productCoverage requires either a documented inadequate response or intolerable adverse event with Bildyos that was not an expected adverse event attributable to the active ingredient, or treatment with the requested product within the past 365 days.

    Denosumab Product Preference

    Billing Rule

    Bildyos preferred over Prolia and other non-preferred products

    Bildyos (denosumab-nxxp) is the preferred denosumab product for Prolia (denosumab) therapy. A non-preferred denosumab product requires an approved clinical exception based on inadequate response or an intolerable adverse event with Bildyos, with the event not being an expected active-ingredient reaction, or prior treatment with the requested product within the past 365 days.

    • Preferred product: Bildyos (denosumab-nxxp)
    • Non-preferred products require an approved clinical exception or prior treatment with the requested product within 365 days
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyDenosumab Products for Osteoporosis and Cancer-Treatment-Related Bone Loss
    Policy CodePolicy N/A
    Change TypeOff-cycle revision with preferred-product update
    Effective DateOctober 1, 2026
    Last ReviewJun 1, 2025
    Next Review DateN/A
    Key ActionPrior authorization is required; providers should use the HMSA medical specialty drug policy website fax form.
    SourceLink
    On This Page
    Covered IndicationsClinical Thresholds and Product HistoryPrior Authorization and DocumentationPolicy BackgroundClinical DefinitionsInitial TherapyContinuation TherapyPreferred Product RequirementDenosumab Product Preference
    Prior treatment with requested non-preferred product
    Lookback periodWithin the past 365 days
    ProductThe requested non-preferred product
    Coverage pathwayPrior treatment may qualify for coverage of a non-preferred product
  1. Preferred or formulary status may still require clinical prior authorization review.
  2. Documentation Required

    Document the Non-Preferred Exception

    For a non-preferred product, document an applicable exception. Coverage may be available when the member had an inadequate response or intolerable adverse event with Bildyos, subject to the policy’s adverse-event requirements, or when the member received the requested non-preferred product within the past 365 days.

    • Document an inadequate response or intolerable adverse event with Bildyos.
    • The adverse event must not be an expected adverse event attributable to the active ingredient or a known reaction described in prescribing information for the reference or biosimilar products.
    • Alternatively, document treatment with the requested non-preferred product during the previous 365 days.
    Documentation Required

    Document Indication and Clinical Eligibility

    Document that the requested drug is being used for a covered indication and provide the clinical facts supporting eligibility. Coverage applies only when approval criteria are met and the member has no exclusions to the prescribed therapy.

    • Osteoporosis treatment in postmenopausal women or men at high risk for fracture, including a history of osteoporotic fracture, multiple fracture risk factors, or failure/intolerance of other available osteoporosis therapy.
    • Glucocorticoid-induced osteoporosis in men or women at high fracture risk who are initiating or continuing systemic glucocorticoids equivalent to at least 7.5 mg prednisone daily and expected to continue for at least 6 months.
    • Increasing bone mass in men at high fracture risk receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    • Increasing bone mass in women at high fracture risk receiving adjuvant aromatase inhibitor therapy for breast cancer.
    • Compendial uses: prophylaxis of osteoporosis in osteopenic postmenopausal women; treatment-related bone loss in prostate cancer receiving androgen deprivation therapy; and treatment in postmenopausal patients with breast cancer receiving adjuvant aromatase inhibition therapy to maintain or improve bone mineral density and reduce fracture risk.
    • For other indications, submit supporting evidence from Medicare-approved compendia; such requests are assessed individually.
    • Authorization may be indefinite for osteoporosis treatment or prevention, and 24 months for prostate cancer, breast cancer, or glucocorticoid-induced osteoporosis indications.
    Documentation Required

    Support Continued Therapy

    For continuation requests, document that the member is currently receiving the requested drug for a covered indication and is benefiting from therapy. Benefit is demonstrated by disease stability or disease improvement.

    • For osteoporosis treatment or prevention: authorization may be indefinite.
    • For all other covered indications: authorization may be granted for 12 months.
    • Document current treatment with the requested drug and disease stability or improvement.
    Denial Risk

    Indication or Eligibility Not Met

    Coverage may be denied when the requested use does not meet a listed covered indication or the required clinical eligibility facts are not documented, including required fracture risk or treatment-related details.

    • The indication is not covered under the policy or lacks supporting evidence for an individually assessed compendial use.
    • Required clinical facts are absent, such as high fracture risk, osteoporosis or osteopenia status, glucocorticoid dose and duration, androgen deprivation therapy, or adjuvant aromatase inhibitor therapy.
    • A member exclusion applies to the prescribed therapy.
    Denial Risk

    Non-Preferred Exception Not Established

    A non-preferred product may be denied when the request does not establish a qualifying exception to the preferred Bildyos requirement.

    • No documented inadequate response or intolerable adverse event with Bildyos.
    • The reported adverse event is an expected or known reaction attributable to the active ingredient.
    • No documentation shows treatment with the requested non-preferred product within the past 365 days.
    Denial Risk

    Continuation Criteria Not Met

    Continuation coverage may be denied when the member is not currently receiving the requested drug, the drug is not being used for a covered indication, or clinical benefit is not documented.

    • No documentation of current therapy with the requested drug.
    • The requested drug is not being used for osteoporosis treatment or prevention, or for another indication enumerated in the coverage criteria.
    • No evidence of benefit, defined as disease stability or disease improvement.
    Expected to remain on glucocorticoids for at least 6 months
    Benefit from therapy
    Benefit standardDisease stability or disease improvement
    Disease stabilityDisease stability qualifies as benefit from therapy
    Disease improvementDisease improvement qualifies as benefit from therapy

    Initial therapy: other covered indications

    Authorization of 24 months may be granted for the following indications.

    ONE of the following covered indications

    • The member is a man at high risk for fracture and is receiving androgen deprivation therapy for prostate cancer.
    • The member is a woman at high risk for fracture and is receiving adjuvant aromatase inhibition therapy for breast cancer.
    • The member is a man or woman with glucocorticoid-induced osteoporosis at high risk for fracture.

      Qualifying systemic glucocorticoid exposure is a daily dosage equivalent to at least 7.5 mg of prednisone, with expected continuation for at least 6 months.

    • The member is currently receiving the requested drug.
    • The requested drug is being used for a covered indication other than osteoporosis treatment or prevention.
    • The member is receiving benefit from therapy.

      Benefit means disease stability or disease improvement.